- Product
- Approval of OTC teleconference bending machine project
- by Kang, Shin-Kook Jun 23, 2022 05:49am
- OTC teleconference bending machine issue, which has been on hold for 10 years, has secured a bridgehead for entering the market under the new government deregulation stance. The Ministry of Science and ICT held an ICT regulatory sandbox review committee on the 20th and approved the OTC teleconference bending machine based on the MOHW's co
- Product
- Prescription of oral COVID-19 drugs drop to 1,800 last week
- by Kang, Shin-Kook Jun 13, 2022 05:54am
- Prescriptions of the oral COVID-19 treatments Paxlovid and Lagevrio have been rapidly decreasing in line with the decrease of confirmed COVID-19 cases in Korea. On the 10th, the Korea Disease Control and Prevention Agency announced that it had prescribed Paxlovid and Lagevrio to 1,800 patients during the past week. From 6:30 p.m. on
- Product
- The supply of Tylenol suspension has been postponed again
- by Kim JiEun May 25, 2022 05:47am
- The sale of children's Tylenol suspension will be extended further. The supplier originally promised to supply it in June, but it seems that it will not be available until August, two months later. Johnson & Johnson Korea recently sent an official letter to drug distributors on the "Delay Notice on the Supply Schedule of Children's Tylenol Suspe
- Product
- Unsure efficacy of Alzheimer's drug aducanumab
- by Choi-sun May 10, 2022 06:07am
- The Korean Dementia Association has reviewed the clinical potential of aducanumab (Aduhelm), the first new drug for Alzheimer's disease to be introduced to the field in 18 years. With the efficacy of the drug under constant debate, and being barely approved for its effect in reducing surrogate biomarkers such as amyloid reduction in Korea and
- Product
- Aftermath of Revlimid of primary benefit multiple myeloma
- by Whang, byung-woo Apr 28, 2022 06:06am
- As Revlimid (Lenalidomide Hemihydrate) based chemotherapy enters the benefit, changes in RRMM prescription patterns are inevitable. Kyprolis-centered KRd therapy (Carfilzomib+Revlimid+Dexamethasone) and Ninlaro-centered IRd therapy ( As both Ixazomib+Revlimid+Dexamethasone) contain Revlimid, there are concerns at the clinical site about how
- Product
- The KPA establishes an emergency TFT
- by Apr 20, 2022 06:05am
- As the presidential transition committee is expected to include the permission of non-face-to-face medical treatment in its national agenda and fully review the revision of the law, the KPA has begun to come up with measures. The Chairman Choi Kwang-hoon formed a TFT related to non-face-to-face treatment and convened his first meeting toda
- Product
- Non-face-to-face tx companies are appealing for regulations
- by Jung, Heung-Jun Apr 20, 2022 06:05am
- Non-face-to-face treatment companies are appealing for regulatory improvement ahead of the abolition of social distancing and easing the level of infectious diseases. Pharmacists are protesting that the reason for non-face-to-face is disappearing and that they should take steps to temporarily terminate the permit as scheduled. According to th
- Product
- Immunity products fare better “targeting the long COVID mkt
- by Apr 19, 2022 05:52am
- The OTC drug trend at pharmacies is changing. Compared to February and March when the Omicron variant had wielded power over the country and sales at pharmacies increased due to a surge in demand for antipyretic analgesics and sore throat treatments, etc., sales of products related to long-term effects of COVID-19 are now increasing due to more
- Product
- Gov discusses presenting regulatory sandboxes for ER OTC
- by Jung, Heung-Jun Apr 18, 2022 05:57am
- The Ministry of Trade, Industry and Energy conducted an opinion survey of government departments on regulatory sandbox agendas related to safety medicines (medications that are urgently used for mild symptoms among general drugs and can be used by patients themselves). If discussions on special regulations on safety medicines begin following
- Product
- Lagevrio prescriptions exceed 2,000… Paxlovid's up 25.6%
- by Kang, Shin-Kook Apr 5, 2022 05:58am
- The number of oral COVID-19 treatment Largevrio’s prescriptions has exceeded 2,000 in only 5 days since it was supplied to pharmacies in Korea. Also, the number of total Paxlovid prescriptions has exceeded 150,000 courses. According to the Korea Disease Control and Prevention Agency on the 1st, a total of 150,321 prescriptions were made fro
